Effects of Linagliptin on Vessel Wall Healing in the Rat Model of Arterial Injury Under Normal and Diabetic Conditions
| Autor: | Malin Kronqvist, Samuel Röhl, Claes-Göran Östenson, Robert Saxelin, Kenneth Caidahl, Mariette Lengquist, Anton Razuvaev, Linnéa Eriksson |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Blood Glucose
Male Neointima medicine.medical_specialty medicine.medical_treatment Linagliptin 030209 endocrinology & metabolism 030204 cardiovascular system & hematology Pharmacology Random Allocation 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Restenosis In vivo Angioplasty Animals Hypoglycemic Agents Medicine Rats Wistar Cell Proliferation Evans Blue Wound Healing Dose-Response Relationship Drug business.industry medicine.disease Rats Surgery Treatment Outcome Diabetes Mellitus Type 2 chemistry Carotid Artery External cardiovascular system Immunohistochemistry Carotid Artery Injuries Cardiology and Cardiovascular Medicine business Wound healing medicine.drug |
| Zdroj: | Journal of Cardiovascular Pharmacology. 69:101-109 |
| ISSN: | 0160-2446 |
| DOI: | 10.1097/fjc.0000000000000447 |
| Popis: | Diabetic patients suffer an increased risk of restenosis and late stent thrombosis after angioplasty, complications which are related to a defective reendothelialization. Dipeptidyl peptidase-4 inhibitors have been suggested to exert a direct effect on endothelial and smooth muscle cells (SMCs). Therefore, the objective was to study if the dipeptidyl peptidase-4 inhibitor linagliptin could influence vascular repair and accelerate reendothelialization after arterial injury in healthy and diabetic animals. Diabetic Goto-Kakizaki and healthy Wistar rats were subjected to arterial injury and treated with linagliptin or vehicle. Vessel wall healing was monitored noninvasively using ultrasound, and on sacrifice, with Evans blue staining and immunohistochemistry. The effect of linagliptin on SMCs was also studied in vitro. We found that linagliptin reduced the proliferation and dedifferentiation of SMCs in vitro, and modulated the inflammatory response in the SMCs after arterial injury in vivo. However, these effects of linagliptin did not affect the neointima formation or the reendothelialization under normal and diabetic conditions. Although linagliptin did not influence vessel wall healing, it seems to possess a desirable antiproliferative influence on SMCs in vitro and an antiinflammatory effect in vivo. These pharmacological properties might carry a potential significance for favorable outcome after vascular interventions in diabetic patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|